Magnesium in Liver Cirrhosis

Study Overview
=================
Brief Summary
-----------------
Several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Detailed Description
-----------------
Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions. There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem. Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis. There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps). The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Official Title
-----------------
Magnesium Deficiency in Cirrhotic Patients

Conditions
-----------------
LIVER CIRRHOSIS

Intervention / Treatment
-----------------
* Dietary Supplement: magnesium
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with liver cirrhosis Exclusion Criteria: pregnant women Patients with acute or chronic renal failure (cr>1.5) Congestive heart failure NYHA 3-4 Patient with active cancer Patients with dementia or mental retardation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: magnesium<br>will get magnesium for 6 weeks | Dietary Supplement: magnesium<br>* supply magnesium oxide for 6 weeks<br>* Other names: magnesium oxide;|
| Placebo Comparator: placebo<br>will get placebo for 6 weeks | Dietary Supplement: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in minimal hepatic encephalopathy |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in muscle weakness |  | 6 weeks after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
LIVER CIRRHOSIS, MAGNESIUM, MINIMAL ENCEPHALOPATHY, MUSCLE WEAKNESS